Hydralazine Dosing
For intravenous hydralazine in hypertensive emergencies, initiate with 10 mg via slow IV infusion (maximum initial dose 20 mg), repeating every 4-6 hours as needed, though hydralazine is not a desirable first-line agent due to unpredictable response and prolonged duration of action. 1, 2, 3, 4, 5, 6
Intravenous Dosing
Adults
- Initial dose: 10 mg via slow IV infusion (maximum initial dose 20 mg)
- Repeat dosing: Every 4-6 hours as needed 1, 2, 3, 6
- Onset: Blood pressure begins to decrease within 10-30 minutes
- Duration: Effect lasts 2-4 hours 1, 2, 3
Critical caveat: The unpredictability of response and prolonged duration of action make hydralazine undesirable as a first-line agent for acute hypertensive emergencies in most patients. 1, 2, 3, 4, 5 Consider nicardipine, clevidipine, or labetalol as preferred alternatives for more predictable blood pressure control.
Pediatric IV Dosing
- Dose: 1.7-3.5 mg/kg/day divided into 4-6 doses, administered intramuscularly or intravenously 6
- Alternative dosing: 0.1-0.2 mg/kg per dose (based on recent pediatric literature) 7
- Important: In a retrospective study of 141 pediatric doses, median dose was 0.10 mg/kg (range 0.02-0.37 mg/kg), with 31% experiencing excessive blood pressure reduction (>25% decrease in MAP), particularly with higher initial blood pressures and higher doses 7
Pediatric safety concern: Higher initial mean arterial pressure and increased hydralazine dose were associated with greater odds of excessive response, while administration of other antihypertensive drugs decreased this risk. 7
Oral Dosing
Adults - Heart Failure
The 2022 ACC/AHA/HFSA guidelines provide specific dosing for heart failure with reduced ejection fraction:
Fixed-dose combination (hydralazine/isosorbide dinitrate):
- Initial: 37.5 mg hydralazine/20 mg isosorbide dinitrate three times daily
- Target: 75 mg hydralazine/40 mg isosorbide dinitrate three times daily
- Mean dose achieved in trials: ~175 mg hydralazine/90 mg isosorbide dinitrate daily 8
Individual components:
- Initial: Hydralazine 25-50 mg three or four times daily AND isosorbide dinitrate 20-30 mg three or four times daily
- Maximum: Hydralazine 300 mg daily in divided doses AND isosorbide dinitrate 120 mg daily in divided doses 9, 8
Adults - Hypertension
- Initial: 10 mg four times daily for 2-4 days
- Increase to: 25 mg four times daily for remainder of first week
- Subsequent weeks: Increase to 50 mg four times daily
- Maintenance: Adjust to lowest effective dose; some patients may be controlled with twice-daily dosing 10
Important: Once-daily conventional hydralazine is unsatisfactory, particularly in rapid acetylators, as the hypotensive effect wanes at 24 hours. 11 Twice-daily dosing provides satisfactory 24-hour control in both rapid and slow acetylators.
Pediatric Oral Dosing
- Initial: 0.75 mg/kg/day in four divided doses
- Titration: Increase gradually over 3-4 weeks
- Maximum: 7.5 mg/kg/day or 200 mg daily, whichever is less 12, 10
Renal Impairment Adjustments
Patients with marked renal damage require lower doses. 6 The pharmacokinetic rationale is compelling:
- Normal GFR: Half-life 1.7-3.0 hours
- GFR 16 mL/min: Half-life increases to 15.8 hours 13
- GFR <30 mL/min: Significant drug accumulation occurs (r=-0.63; p<0.01) 13
Practical approach: For patients with GFR <30 mL/min, start with 50% of the usual dose and titrate cautiously based on blood pressure response and monitoring for adverse effects. The slower elimination is likely due to decreased metabolic conversion rather than reduced renal excretion. 13
Acetylator Status Considerations
Acetylator phenotype significantly affects dosing requirements:
- Slow acetylators: D50 = 0.87 mg/kg daily
- Fast acetylators: D50 = 1.68 mg/kg daily (nearly double) 14
- Maximum effect (Emax): 9.4 mm Hg reduction in diastolic blood pressure 14
Slow acetylators achieve greater blood pressure reduction at lower doses and are at higher risk for drug-induced lupus syndrome with prolonged use. 10
Critical Safety Considerations
Administration Guidelines
- Use immediately after vial opening 6
- Do not add to infusion solutions 6
- Discard discolored solutions (may occur upon contact with metal) 6
- Check blood pressure frequently after IV administration 6
- Monitor for hypotension, especially in patients with increased intracranial pressure where lowering blood pressure may increase cerebral ischemia 6
Drug Interactions
- MAO inhibitors: Use with extreme caution 6, 10
- Diazoxide: Profound hypotensive episodes may occur with concomitant use; continuous observation required for several hours 6, 10
- Beta-blockers: Concomitant therapy induces additional 6.6 mm Hg blood pressure drop beyond hydralazine effect 14
Transition to Oral Therapy
Most patients can be transferred from IV to oral hydralazine within 24-48 hours. 6